Respiratory Tract Diseases  >>  onalespib (AT13387)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
onalespib (AT13387) / Otsuka
NCT01712217 / 2012-001575-37: A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Checkmark From study AT13387 of crizotinib in combination with onalespib in NSCLC at ASCO 2016
Jun 2016 - Jun 2016: From study AT13387 of crizotinib in combination with onalespib in NSCLC at ASCO 2016
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2016
More
Completed
1/2
220
US, Canada, Europe, RoW
AT13387, Crizotinib, Xalkori
Astex Pharmaceuticals, Inc.
Non-small Cell Lung Cancer(NSCLC)
12/16
05/17

Download Options